Evidence map›Paper›PMID 37190020›Full record

ArticleCells2023

Partial Inhibition of Complex I Restores Mitochondrial Morphology and Mitochondria-ER Communication in Hippocampus of APP/PS1 Mice.

Jessica Panes, Thi Kim Oanh Nguyen, Huanyao Gao, Trace A Christensen, Andrea Stojakovic, Sergey Trushin, Jeffrey L Salisbury, Jorge Fuentealba, Eugenia Trushina

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jessica PanesDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-5501-6582
Thi Kim Oanh NguyenDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-6068-6222
Huanyao GaoDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-9441-9579
Trace A ChristensenMicroscopy and Cell Analysis Core Facility, Mayo Clinic, Rochester, MN 55905, USA.
Andrea StojakovicDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Sergey TrushinDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Jeffrey L SalisburyMicroscopy and Cell Analysis Core Facility, Mayo Clinic, Rochester, MN 55905, USA.
Jorge FuentealbaDepartment of Physiology, Universidad de Concepcion, Concepción 4030000, Chile.
Eugenia TrushinaDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Mayo Clinic · USMayo Clinic in Florida · USUniversity of Concepción · CL

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI CHERYL LYNN WILLMAN · 1985 to 2026
$151.3M
Mitochondrial Complex I as a Target for Neuroprotection in ADRF1AG055549 · NIA · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2017 to 2025
$7.0M
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to TreatmentRF1AG059093 · NIA · DUKE UNIVERSITY · PI BRINTON, ROBERTA EILEEN, CHANG, RUI · 2018 to 2018
$5.9M
AMP-Kinase as a target for neuroprotection in ADRF1AG062135 · NIA · UNIVERSITY OF MINNESOTA · PI LEE, MICHAEL K, TRUSHINA, EUGENIA · 2019 to 2019
$3.2M
Inflammasome activation in modulation of Alzheimer’s Disease by alcohol Administrative SupplementR01AG072899 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GOLENBOCK, DOUGLAS T, SZABO, GYONGYI · 2020 to 2025
$2.4M
Small molecule mitochondria-targeted therapeutics for Huntingtons DiseaseR01NS107265 · NINDS · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2018 to 2021
$2.2M
Chronic Alcohol Exposure and Pathophysiology of Alzheimer's Disease.R01AG072898 · NIA · MAYO CLINIC ROCHESTER · PI CHOI, DOO-SUP, TRUSHINA, EUGENIA · 2020 to 2024
$2.0M
Small Molecule Mitochondria-Targeted Therapeutics for AD (Supplement)UH3NS113776 · NINDS · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2022 to 2022
$1.1M
Small molecule mitochondria-targeted therapeutics for ADUG3NS113776 · NINDS · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2021 to 2021
$785k
NCI NIH HHS P30 CA015083NIA NIH HHS R01 AG072898NIA NIH HHS RF1 AG055549NIA NIH HHS RF1 AG059093NIA NIH HHS RF1 AG062135NIH HHS AG072899NIH HHS AG59093NIH HHS R01NS107265NIH HHS RF1AG55549NIH HHS RO1AG062135NIH HHS UG3/UH3NS 113776NINDS NIH HHS R01 NS107265NINDS NIH HHS UH3 NS113776
6 · The paper itself

Abstract

Alzheimer's disease (AD) has no cure. Earlier, we showed that partial inhibition of mitochondrial complex I (MCI) with the small molecule CP2 induces an adaptive stress response, activating multiple neuroprotective mechanisms. Chronic treatment reduced inflammation, Aβ and pTau accumulation, improved synaptic and mitochondrial functions, and blocked neurodegeneration in symptomatic APP/PS1 mice, a translational model of AD. Here, using serial block-face scanning electron microscopy (SBFSEM) and three-dimensional (3D) EM reconstructions combined with Western blot analysis and next-generation RNA sequencing, we demonstrate that CP2 treatment also restores mitochondrial morphology and mitochondria-endoplasmic reticulum (ER) communication, reducing ER and unfolded protein response (UPR) stress in the APP/PS1 mouse brain. Using 3D EM volume reconstructions, we show that in the hippocampus of APP/PS1 mice, dendritic mitochondria primarily exist as mitochondria-on-a-string (MOAS). Compared to other morphological phenotypes, MOAS have extensive interaction with the ER membranes, forming multiple mitochondria-ER contact sites (MERCS) known to facilitate abnormal lipid and calcium homeostasis, accumulation of Aβ and pTau, abnormal mitochondrial dynamics, and apoptosis. CP2 treatment reduced MOAS formation, consistent with improved energy homeostasis in the brain, with concomitant reductions in MERCS, ER/UPR stress, and improved lipid homeostasis. These data provide novel information on the MOAS-ER interaction in AD and additional support for the further development of partial MCI inhibitors as a disease-modifying strategy for AD.

Indexed as

Alzheimer DiseaseAnimalsEndoplasmic ReticulumHippocampusLipidsMiceMice, TransgenicMitochondriaLipidsAlzheimer’s disease (AD)endoplasmic reticulum (ER)mitochondriaserial block-face scanning electron microscopy (SBFSEM)small molecule mitochondria targeted therapeuticsthree-dimensional electron microscopy (3DEM)

Identifiers

PMID37190020
PMCPMC10137328
OpenAlexW4363648005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.